Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis
ABSTRACT Background Myelodysplastic syndromes (MDS) encompass a heterogeneous group of haematological neoplasms characterized by ineffective haematopoiesis and a variable risk of transformation to acute myeloid leukaemia (AML). Elevated serum ferritin (SF), a marker of iron overload (IO), has been l...
Saved in:
| Main Authors: | Gloria Moreno Carrasco, Rodolfo Matias Ortiz Flores, Regina García Delgado, Borja Cidoncha Morcillo, Ana Isabel Rosell Mas, Dana Díaz Canales, María Rodríguez González, Manuel Carrasco Gomariz, Alejandro Escamilla‐Sánchez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transcriptomic analysis of non-leukemic cell subsets in azacytidine-responsive AML highlights pathways associated with adhesion, platelet aggregation, and angiogenesis in mice and humans
by: Nancy D. Ebelt, et al.
Published: (2025-05-01) -
New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
by: E. V. Morozova, et al.
Published: (2022-11-01) -
Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01) -
Polydatin exerts therapeutic effects on myelodysplastic syndrome by inhibiting the protein expression of oncogenes via hypermethylation in vitro
by: Qingbing Zhou, et al.
Published: (2025-05-01) -
Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)